Original article

High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects

Deborah Watson-Jones,1,2 Kathy Baisley,1 Joelle Brown,1,2 Bazil Kavishe,2 Aura Andreasen,1,2 John Changalucha,3 Philippe Mayaud,1 Saidi Kapiga,1,2 Balthazar Gumodoka,4 Richard J Hayes,1 Silvia de Sanjose5,6

Abstract

Objectives We measured the prevalence and incidence of human papillomavirus (HPV) infection in young female subjects recruited for a safety and immunogenicity trial of the bivalent HPV-16/18 vaccine in Tanzania.

Methods Healthy HIV negative female subjects aged 10–25 years were enrolled and randomised (2:1) to receive HPV-16/18 vaccine or placebo (Al(OH)3 control). At enrolment, if sexually active, genital specimens were collected for HPV DNA, other reproductive tract infections and cervical cytology. Subjects were followed to 12 months when HPV testing was repeated.

Results In total 334 participants were enrolled; 221 and 113 in vaccine and control arms, respectively. At enrolment, 74% of 142 sexually active subjects had HPV infection of whom 69% had >1 genotype. Prevalent infections were HPV-45 (16%), HPV-53 (14%), HPV-16 (13%) and HPV-58 (13%). Only age was associated with prevalent HPV infection at enrolment. Among 23 girls who reported age at first sex as 1 year younger than their current age, 15 (65.2%) had HPV infection. Of 187 genotype-specific infections at enrolment, 51 (27%) were present at 12 months. Overall, 67% of 97 sexually active participants with results at enrolment and 12 months had a new HPV genotype at follow-up. Among HPV uninfected female subjects at enrolment, the incidence of any HPV infection was 76 per 100 person-years.

Conclusions Among young women in Tanzania, HPV is highly prevalent and acquired soon after sexual debut. Early HPV vaccination is highly recommended in this population.

Introduction

The primary cause of cervical cancer is persistent infection with high risk (HR) human papillomavirus (HPV) genotypes. East Africa has one of the highest rates of cervical cancer in the world.1 Reviews of global age-specific prevalence show a high prevalence of HPV in young sexually active women,2–4 but there are few data on the epidemiology of HPV infection in sexually active girls and young women aged <25 years in East Africa, where prevalences have been reported as high as 55% in Mozambique.5 We measured the burden of HPV infection and risk factors for infection in a cohort of HIV negative girls and young women aged 10–25 years in Tanzania recruited for a safety and immunogenicity trial of a prophylactic HPV vaccine.5 These data will be used to help to inform recommended age of HPV vaccination in a future national vaccination programme.

Methods

Study design

This substudy was nested within a Phase IIIb immunogenicity and safety study of the HPV-16/18 AS04-adjuvanted vaccine. This double-blind, randomised, controlled trial (NCT00481767) was conducted in Dakar, Senegal and Mwanza, Tanzania, with eligible female subjects being randomly assigned (2:1) to receive either three doses of vaccine (vaccine group) or Al(OH)3 (control group).6 Trial results have been published elsewhere. The HPV substudy was conducted between October 2007 and July 2010 in Mwanza.6 The trial and the substudy were approved by the ethics committees of the National Institute for Medical Research (NIMR), Tanzania and the London School of Hygiene & Tropical Medicine.

Study participants

Study participants were recruited from schools, colleges and family planning clinics in Mwanza and invited to attend an eligibility screening visit 1 month before enrolment. They were eligible if they were aged 10–25 years, HIV negative, not pregnant, had ≤6 lifetime sexual partners, were free of health problems, had no history of neurological disorders and, if sexually active, were willing to use contraception or abstain from sex for 30 days before vaccination until 2 months after completion of vaccination. This was requested for all participants and contraception was provided at the research clinic (the majority (75%) of sexually active women used hormonal contraception throughout the study). Participants were asked for written consent or, if illiterate, for witnessed thumbprinted informed consent. Parental/guardian consent was obtained for participants aged below 18 years.

Follow-up procedures

Participants were followed to month 12. HPV vaccine (Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) or the control injection was given at months 0, 1 and 6.

Specimen collection

Blood samples were collected at the screening visit (day 30) for HIV and syphilis. At enrolment...
(month 0), before vaccination, participants were interviewed about sexual activity and, if sexually active, symptoms of reproductive tract infections. A genital examination was performed on participants who reported ever being sexually active. Vaginal swabs were taken for bacterial vaginosis (BV) and Trichomonas vaginalis (TV). A Papanicoulov smear was taken and an endocervical swab was collected for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). An ectocervical swab and endocervical swab were also taken for HPV DNA testing at enrolment and month 12 from participants who reported ever being sexually active. Syndromic reproductive tract infection treatment was provided and treatment was offered for NG, CT, TV and symptomatic BV diagnosed on laboratory testing.

Laboratory tests
Cervical swabs for HPV DNA testing were frozen at −20°C and sent to the Catalan Institute of Oncology in Barcelona where they were genotyped for 37 different HPV genotypes by the Roche Linear Array assay (Roche, Branchburg, USA) according to the manufacturer’s instructions. The PCR reaction included an additional primer pair targeting the human β-globin gene as an internal control. Genotyping was performed in an automated system, Auto-LiPA 48 (Tecan Austria GmbH, distributed by Innogenetics). HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59 and -68 were considered HR genotypes; all other genotypes were considered low risk (LR).

Papanicoulov smears were processed and results recorded from a single reading in Mwanza. Endocervical swabs were tested for NG and CT by PCR (AMPLICOR, Roche, Branchburg, USA) in Mwanza. Gram stained vaginal smears were examined for Candida albicans spores and for BV using the Nugent score while TV was diagnosed by culture (InPouch TV, BioMed Diagnostics, San Jose, California, USA).

HIV serology was determined using two rapid tests, Determine HIV-1/2 (Alere Medical Co., Matsudo-shi, Chiba, Japan) and SD Bioline HIV-1/2 3.0 (SD Standard Diagnostics, Inc. Hagal-dong, Kyonggi-do, Korea). Positive, indeterminate or discordant results were confirmed by an HIV Ag–Ab combination ELISA (Murex Biotech, Dartford, UK) and Uni-Form II Ag–Ab micro ELISA (bioMérieux, Basingstoke, UK). Discordant samples on ELISA were tested for P24 antigen (Biorad, Genetic Systems, UK). Serum samples were tested for syphilis by the rapid plasma reagin test (Immutrep, Omega Diagnostics, Alva, UK) and Treponema pallidum particle agglutination assay (Fujirebio, Tokyo, Japan).

Statistical analysis
Data were double entered and verified in DMSys (SigmaSoft International), and analysed using STATA V11.0 (StataCorp LP; College Station, Texas, USA).

The trial aimed to enrol 333 participants in Mwanza (222 and 111 participants in the vaccine and control arms, respectively). Enrolment was age-stratified, with a third of participants in the 15–25 years age-stratum and the remainder in the 10–14 years age-stratum.

Cohort characteristics at enrolment were tabulated and HPV genotype prevalence was calculated among sexually active participants. The number of new infections (genotype not present at enrolment, present at month 12), persistent infections (same genotype at enrolment and month 12) and cleared infections (positive for the genotype at enrolment but negative for that genotype at month 12) were tabulated by treatment arm and overall. Type-specific persistence and clearance were calculated among women who were infected with the genotype at enrolment. Type-specific cumulative incidence was calculated among those who were negative for the genotype at enrolment. The proportion of women with any new HPV infection, any persistence and any clearance were calculated among all women who had samples at both time points.

The incidence rate (per 100 person-years) of any HPV genotype, and any HR genotype, was calculated among women who were negative for all genotypes, or negative for all HR genotypes, respectively, at enrolment. Person-years at risk were calculated from date of enrolment until date of HPV acquisition, assumed to occur mid-way between the last negative and first positive results.

Risk factors associated with prevalent HPV infection at enrolment among sexually active participants were analysed using logistic regression to estimate OR and 95% CI. Participants who were positive for any HPV genotype were classed as ‘infected’; those negative for all HPV genotypes were classed as ‘uninfected’. Age was considered an a priori confounder, and so was included in all models. Factors that were associated with HPV infection at p<0.20 in the age-adjusted analysis were considered for inclusion in a multivariable model; those remaining independently associated at p<0.10 were retained. After age-adjustment, no other variables were associated with HPV infection at p<0.10, and so no further model building was done.

RESULTS
Cohort screening, enrolment and follow-up
In total, 387 participants attended the screening visit. Of 379 eligible female subjects, 334 (88.1%) were enrolled (221 and 113 in the vaccine and control arms, respectively); 45 refused, 15 had moved away, 16 did not attend the visit and 25 were not enrolled because the enrolment target had been reached. The median age of enrolled participants was 18 years (IQR 13–19).

Overall, 308/334 (92.2%) participants attended the month 12 visit; 206 (93.2%) in the vaccine arm and 102 (90.3%) in the placebo arm (p=0.34).

Reasons for not completing follow-up included withdrawal of consent (10), moved away (4), temporary travel (5), being untraceable (3) and unknown reason (4).

Cohort description at enrolment
Approximately half (46.5%) of 334 enrolled participants had secondary school or higher education; 78.2% were currently students. Most (87.4%) were single. Only 2 (0.6%) had ever smoked and 4 (1.3%) had vulval genital warts. No cervico-vaginal warts were observed.

At enrolment, 142 (42.5%) participants reported having passed their sexual debut; median reported age at first sex was 16 years (IQR 15–17), and 75 (52.8%) reported ≥1 lifetime sexual partner. Two-thirds (66.0%) of sexually active women reported never using condoms. Cervical and vaginal samples were available for 117 (82.4%) and 125 (88.0%) participants, respectively. One participant had congenital absence of a cervix and samples for NG, CT and HPV were taken from the vaginal vault. There were no cases of low or high grade squamous intraepithelial lesions on cervical cytology. Overall 27.4% had BV, 12.8% had TV, 5.1% had CT and 2.6% had NG. Two participants (1.4%) had active syphilis.

Prevalence of HPV at enrolment by genotype, age and recent sexual debut
Overall 73.5% (86/117; 95% CI 64.5 to 81.2) of sexually active participants with HPV results at enrolment had HPV infection (table 1). Assuming that girls who had not had sex were HPV
negative, the overall cohort HPV prevalence was 27.8% (86/309). In total, 54.7% (64/117) of sexually active participants were infected with HR genotypes. The most common (figure 1) were HPV-45 (16.2%), HPV-16 (12.8%) and HPV-58 (12.8%). Seventeen participants (14.5%) were infected with either HPV-16 or -18. The most common LR genotype was HPV-53 (13.7%).

In sexually active female subjects, HPV prevalence was 36% (4/11) in those aged ≤ 16 years, increased to 86% (18/21) in 19–20-year-olds, then declined to 64% (18/28) in those aged ≥ 23 years (table 2). Assuming that female subjects who were not sexually active were HPV negative, cohort HPV prevalence was 3% in those aged ≤ 16 years, then showed a similar trend of rapid

---

**Table 1** HPV prevalence at enrolment and at 12 months among sexually active subjects

|                      | Enrolment |                      |                      |                      |                      |
|----------------------|-----------|----------------------|----------------------|----------------------|----------------------|
|                      | Control   | Vaccine              | Total                | Control              | Vaccine              | Total                |
| Swab results available/sexually active | 33/47 (70.2) | 84/95 (88.4) | 117/142 (82.4) | 37/45 (82.2) | 85/91 (93.4) | 122/136 (89.7) |
| Any HPV type         |           |                      |                      |                      |                      |                      |
| Yes                  | 25 (75.8) | 61 (72.6)            | 86 (73.5)            | 25 (67.6)           | 66 (77.6)           | 91 (74.6)            |
| Any high risk HPV    |           |                      |                      |                      |                      |                      |
| Yes                  | 18 (54.5) | 46 (54.8)            | 64 (54.7)            | 12 (32.4)           | 50 (58.8)           | 62 (50.8)            |
| HPV 16/18            |           |                      |                      |                      |                      |                      |
| Yes                  | 4 (12.1)  | 13 (15.5)            | 17 (14.5)            | 3 (8.1)             | 5 (5.9)             | 8 (6.6)              |
| Number of HPV genotypes |         |                      |                      |                      |                      |                      |
| None                 | 8 (24.2)  | 23 (27.4)            | 31 (26.5)            | 12 (32.4)           | 19 (22.4)           | 31 (25.4)            |
| 1                    | 7 (21.2)  | 20 (23.8)            | 27 (23.1)            | 11 (29.7)           | 18 (21.2)           | 29 (23.8)            |
| 2                    | 9 (27.3)  | 16 (19.0)            | 25 (21.4)            | 2 (5.4)             | 19 (22.4)           | 21 (17.2)            |
| 3                    | 4 (12.1)  | 11 (13.1)            | 15 (12.8)            | 4 (10.8)            | 14 (16.5)           | 18 (14.8)            |
| 4 or more            | 5 (15.2)  | 14 (16.7)            | 19 (16.2)            | 8 (21.6)            | 15 (17.6)           | 23 (18.9)            |
| Swab results available at both visits/sexually active at both visits | 24/39 (61.5) | 73/84 (86.9) | 97/123 (78.9) |
| Any new HPV type     |           |                      |                      |                      |                      |                      |
| Yes                  | 16 (66.7) | 49 (67.1)            | 65 (67.0)            |                      |                      |                      |
| Any new high risk HPV|           |                      |                      |                      |                      |                      |
| Yes                  | 7 (29.2)  | 34 (46.6)            | 41 (42.3)            |                      |                      |                      |
| Any new HPV-16/18    |           |                      |                      |                      |                      |                      |
| Yes                  | 2 (8.3)   | 1 (1.4)              | 3 (3.1)              |                      |                      |                      |
| Any persistent HPV   |           |                      |                      |                      |                      |                      |
| Yes                  | 10 (41.7) | 22 (30.1)            | 32 (33.0)            |                      |                      |                      |
| Any persistent high risk HPV |      |                      |                      |                      |                      |                      |
| Yes                  | 5 (20.8)  | 16 (21.9)            | 21 (21.6)            |                      |                      |                      |

HPV, human papillomavirus.

---

**Figure 1** Prevalence of human papillomavirus (HPV) by genotype in 117 sexually active girls at enrolment.
Table 2  Cervical HPV infection at enrolment and associated factors among 117 sexually active subjects

| Sociodemographic factors | No with HPV/number sexually active (%) | Unadjusted OR (95% CI) | Age-adjusted OR (95% CI) |
|--------------------------|----------------------------------------|------------------------|--------------------------|
| **Age group (years)**    |                                        |                        |                          |
| ≤16                      | 4/11 (36.4)                            | 0.13 (0.03 to 0.60)    | 0.13 (0.03 to 0.60)      |
| 17–18                    | 26/32 (81.2)                           | 1                      | 1                        |
| 19–20                    | 18/21 (85.7)                           | 1.38 (0.31 to 6.27)    | 1.38 (0.31 to 6.27)      |
| 21–22                    | 20/25 (80.0)                           | 0.92 (0.25 to 3.46)    | 0.92 (0.25 to 3.46)      |
| 23+                      | 18/28 (64.3)                           | 0.42 (0.13 to 1.35)    | 0.42 (0.13 to 1.35)      |
| **Religion**             |                                        |                        |                          |
| Catholic                 | 36/49 (73.5)                           | 1                      | 1                        |
| Other Christian          | 26/36 (72.2)                           | 0.94 (0.36 to 2.47)    | 0.84 (0.29 to 2.42)      |
| Muslim                   | 24/32 (75.0)                           | 1.08 (0.39 to 3.01)    | 1.47 (0.49 to 4.45)      |
| **Education level**      |                                        |                        |                          |
| Less than primary        | 11/14 (78.6)                           | 1                      | 1                        |
| Primary                  | 32/46 (69.6)                           | 0.62 (0.15 to 2.59)    | 0.59 (0.13 to 2.73)      |
| Secondary or above       | 43/57 (75.4)                           | 0.84 (0.20 to 3.44)    | 0.64 (0.13 to 3.10)      |
| **Marital status**       |                                        |                        |                          |
| Single                   | 57/76 (75.0)                           | 1                      | 1                        |
| Married                  | 27/39 (69.2)                           | 0.75 (0.32 to 1.76)    | 0.66 (0.20 to 2.16)      |
| Separated/divorced       | 2/2 (100)                              | –                      | –                        |
| **Number of children ever had** |                                  |                        |                          |
| None                     | 45/62 (72.6)                           | 1                      | 1                        |
| 1                        | 22/31 (71.0)                           | 0.92 (0.36 to 2.40)    | 0.71 (0.22 to 2.32)      |
| 2 or more                | 19/24 (79.2)                           | 1.44 (0.46 to 4.45)    | 1.32 (0.32 to 5.41)      |
| **Behavioural factors**  |                                        |                        |                          |
| **Lifetime partners**    |                                        |                        |                          |
| 1                        | 35/47 (74.5)                           | 1                      | 1                        |
| 2–3                      | 36/48 (75.0)                           | 1.03 (0.41 to 2.66)    | 0.76 (0.27 to 2.17)      |
| 4–5                      | 15/22 (68.2)                           | 0.73 (0.24 to 2.23)    | 0.59 (0.17 to 2.07)      |
| **Age at first sex (years)** |                                    |                        |                          |
| ≤14                      | 10/17 (58.8)                           | 1                      | 1                        |
| 15–16                    | 35/48 (72.9)                           | 1.88 (0.59 to 5.99)    | 1.53 (0.41 to 5.71)      |
| 17–18                    | 31/37 (83.8)                           | 3.73 (1.02 to 13.72)   | 2.66 (0.58 to 12.20)     |
| 19+                      | 9/14 (64.3)                            | 1.26 (0.29 to 5.42)    | 1.18 (0.20 to 6.97)      |
| **Time since first sex (years)** |                                    |                        |                          |
| ≤1 year                  | 19/29 (65.5)                           | 1                      | 1                        |
| 2–3 years                | 26/34 (76.5)                           | 1.71 (0.57 to 5.15)    | 1.29 (0.38 to 4.41)      |
| 4–5 years                | 21/25 (84.0)                           | 2.76 (0.74 to 10.29)   | 2.23 (0.49 to 10.17)     |
| >5 years                 | 20/29 (69.0)                           | 1.17 (0.39 to 3.51)    | 1.27 (0.28 to 5.81)      |
| **Condom use**           |                                        |                        |                          |
| Never                    | 53/79 (67.1)                           | 1                      | 1                        |
| Sometimes                | 11/12 (91.7)                           | 5.40 (0.66 to 44.08)   | 4.69 (0.54 to 40.51)     |
| Often/always             | 22/26 (84.6)                           | 2.70 (0.84 to 8.64)    | 2.64 (0.76 to 9.16)      |
| **Using hormonal contraception at screening** |    |                        |                          |
| No                       | 52/76 (68.4)                           | 1                      | 1                        |
| Yes                      | 34/41 (82.9)                           | 2.24 (0.87 to 5.78)    | 2.07 (0.71 to 5.97)      |
| **Clinical factors**     |                                        |                        |                          |
| **Ectopy**               |                                        |                        |                          |
| None                     | 64/89 (71.9)                           | 1                      | 1                        |
| <20%                     | 19/23 (82.6)                           | 1.86 (0.57 to 6.00)    | 2.17 (0.63 to 7.52)      |
| 20%–50%                  | 3/5 (60.0)                             | 0.59 (0.09 to 3.72)    | 0.53 (0.08 to 3.75)      |
| **Age at menarche (years)** |                                    |                        |                          |
| ≤13                      | 14/24 (58.3)                           | 1                      | 1                        |
| 14                       | 22/31 (71.0)                           | 1.75 (0.57 to 5.36)    | 1.38 (0.41 to 4.70)      |
| 15                       | 23/29 (79.3)                           | 2.74 (0.82 to 9.19)    | 2.86 (0.77 to 10.59)     |
| 16+                      | 27/33 (81.8)                           | 3.21 (0.97 to 10.68)   | 2.78 (0.74 to 10.48)     |
| **Vaginal flora**        |                                        |                        |                          |
| Negative                 | 50/65 (76.9)                           | 1                      | 1                        |
| Positive (BV)            | 22/32 (68.8)                           | 0.66 (0.26 to 1.70)    | 0.83 (0.30 to 2.30)      |
| Intermediate             | 14/20 (70.0)                           | 0.70 (0.23 to 2.14)    | 0.75 (0.23 to 2.46)      |

Continued

Watson-Jones D, et al. Sex Transm Infect 2013;89:358–365. doi:10.1136/sextrans-2012-050685
increase with age, followed by a gradual decline (see online supplementary figure S1).

Among HPV infected participants, 68.6% (59/86) were infected with >1 genotype.

Of six participants who reported age at sexual debut as their current age, 4 (66.6%) were HPV infected. Among 23 girls who reported age at first sex as 1 year younger than their current age, 15 (65.2%) had HPV infection.

Factors associated with prevalent HPV infection at enrolment

In the unadjusted analysis (table 2), HPV prevalence was higher among participants who reported sometimes or often using condoms than among those who reported never using condoms (p=0.05). There was some evidence that HPV prevalence was higher among participants using hormonal contraception (combined oral contraceptives, depot medroxyprogesterone acetate or implants) at screening (p=0.08). There was no evidence of an association with lifetime partners, age at first sex or marital status, education, religion, parity and other STIs.

In the adjusted analysis, only age remained significantly associated with HPV infection at p<0.10. Compared with participants aged 17–18 years, those aged <17 years had lower odds of HPV infection (adjusted OR 0.19, 95% CI 0.04 to 0.90). The odds of infection were also lower in female subjects aged 17 years, those aged <17 years had lower odds

Table 2 Continued

| Chlamydia trachomatis or Neisseria gonorrhoeae | No with HPV/number sexually active (%) | Unadjusted OR (95% CI) | Age-adjusted OR (95% CI) |
|-----------------------------------------------|---------------------------------------|------------------------|--------------------------|
| Negative                                      | 80/109 (73.4)                         | p=0.92                 | p=0.52                   |
| Positive                                      | 6/8 (75.0)                            | 1                      | 1                        |
| 1.09 (0.21 to 5.70)                           | 1.80 (0.28 to 11.37)                  |
| Trichomonas vaginalis                        | 77/102 (75.5)                         | p=0.22                 | p=0.76                   |
| Negative                                      | 9/15 (60.0)                           | 1                      | 1                        |
| 0.49 (0.16 to 1.50)                           | 0.82 (0.22 to 2.97)                   |
| Syphilis serology*                           | 84/114 (73.7)                         | -                      | -                        |
| Negative                                      |                                       | -                      | -                        |
| Past infection                                |                                       | -                      | -                        |
| Active infection                              | 2/2 (100)                             | -                      | -                        |

*Negative defined as negative on both TPPA and RPR. Past infection defined as positive on TPPA and negative on RPR. Active infection defined as positive on both TPPA and RPR.

Cumulative incidence of HR genotypes ranged from 1% to 12%, and was highest for HPV-51 (12.9%), HPV-39 (12.1%) and HPV-35 (8.7%) in the vaccine arm, and HPV-51 (9.1%), HPV-16 (4.8%) and HPV-58 (4.8%) in the control arm. LR genotypes cumulative incidence ranged from 2% to 10%, being highest for HPV-66 (8.7%), HPV-67 (8.5%) and HPV-61 (7.4%) in the vaccine arm, and HPV-53 (21.7%), HPV-66 (13.6%) and HPV-61 (9.1%) in the control arm.

In the control arm, there was one new HPV-16 and one new HPV-18 infection. In the vaccine arm, there was one new HPV-18 infection; the subject received two doses of vaccine.

Among HPV uninfected participants at enrolment, the incidence of any HPV infection was 76 (95% CI 46 to 126) per 100 person-years. Among those negative for all HR genotypes, the incidence of HR HPV infection was 51 (95% CI 46 to 126) per 100 person-years. Among those negative for all LR genotypes, the incidence of LR HPV infection was 54 (95% CI 33 to 82) per 100 person-years.

Of 97 participants who had HPV results at both time points, 65 (67.0%) were infected with a new HPV genotype by month 12 (table 1), 32 (33%) had persistent infection with ≥1 genotype and 62 (63.9%) had cleared ≥1 genotype by month 12. Only 11/70 (15.7%) participants who were infected at enrolment had cleared all their infections by month 12.

**DISCUSSION**

An extremely high prevalence of HPV infection was observed in HIV negative sexually active girls and young women with normal cervical cytology in Tanzania. HPV-45, -16, -58 and -52 were the most prevalent types. The most common types worldwide in women with normal cytology in a large meta-analysis also included HPV-16 and -58 as well as other HPV genotypes that were less common in our study (HPV-18, -52, -31). In women with normal cervical cytology and in cervical cancer cases, HPV-45 was reported to be more common in sub-Saharan Africa and Latin America than other regions. In the present study, infection with multiple HPV types was common and observed in over 50% of the sexually active cohort. Younger age (<30 years) has been associated with multiple cervical HPV infections in many studies, including population-based studies in Colombia and a trial cohort in the
UK. This may be due to a lack of natural immunity to HPV during the initial years of sexual activity but may also be due to numbers and characteristics of sexual partners.

A number of factors including age, number of sexual partners, age at menarche, hormonal contraceptives, HIV infection and smoking have been associated with HPV infection. Younger age at sexual debut was not associated with HPV infection although this was associated with HR HPV in population-based studies in Nigeria and Uganda. Cigarette smoking, rare in our study population, was associated with HR HPV in the above Ugandan study and has been associated with prevalent and persistent HPV in other countries. Although our OR point estimates suggest that there may be an association with

Table 3 Cumulative HPV incidence over 1 year, persistence and clearance among 97 women with results available at enrolment and 12 months, by HPV genotype

| HPV Type  | Control (N=24 women) | Vaccine (N=73 women) | Total (N=97 women) |
|-----------|---------------------|---------------------|--------------------|
|           | Infected at visit 1 | Persistent* Cleared* Newt | Infected at visit 1 | Persistent* Cleared* Newt | Infected at visit 1 | Persistent* Cleared* Newt |
| High risk |                     |                     |                    |                     |                     |                     |
| HPV-16    | 3                   | 3 (100%)            | 1 (4.8%)          | 11                  | 4 (36.4%)           | 7 (63.6%)           | 0 (0%)              |
| HPV-18    | 1                   | 1 (100%)            | 1 (4.4%)          | 0                   | –                   | –                   | 1 (1.4%)            |
| HPV-31    | 0                   | –                   | 0 (0%)            | 3                   | 1 (33.3%)           | 2 (66.7%)           | 3 (4.3%)            |
| HPV-33    | 1                   | 1 (100%)            | 0 (0%)            | 2                   | 1 (50.0%)           | 1 (50.0%)           | 2 (2.8%)            |
| HPV-35    | 1                   | 1 (100%)            | 0 (0%)            | 4                   | 2 (50.0%)           | 2 (50.0%)           | 6 (8.7%)            |
| HPV-39    | 1                   | 1 (100%)            | 1 (4.4%)          | 7                   | 1 (14.3%)           | 6 (85.7%)           | 8 (12.1%)           |
| HPV-45    | 4                   | 4 (100%)            | 0 (0%)            | 13                  | 1 (7.7%)            | 12 (92.3%)          | 3 (5.0%)            |
| HPV-51    | 2                   | 1 (50.0%)           | 1 (50.0%)         | 2 (9.1%)            | 1 (33.3%)           | 2 (66.7%)           | 9 (12.9%)           |
| HPV-52    | 1                   | 1 (100%)            | –                 | 7                   | 2 (28.6%)           | 5 (71.4%)           | 4 (6.1%)            |
| HPV-56    | 2                   | –                   | 2 (100%)          | 0 (0%)              | –                   | –                   | 3 (4.1%)            |
| HPV-58    | 3                   | 1 (33.3%)           | 2 (66.7%)         | 9                   | 3 (33.3%)           | 6 (66.7%)           | 0 (0%)              |
| HPV-59    | 2                   | 1 (50.0%)           | 1 (50.0%)         | 0 (0%)              | –                   | 2 (100%)           | 3 (4.2%)            |
| HPV-68    | 2                   | 1 (50.0%)           | –                 | 2 (100%)            | 1 (50.0%)           | 6 (85.0%)           | 4 (7.5%)            |
| All high risk infections† | 23                 | 7 (30.4%)           | 16 (69.6%)        | 9                   | 63                  | 17 (27.0%)          | 46 (73.0%)          |
| Low risk  |                     |                     |                    |                     |                     |                     |                    |
| HPV-6     | 2                   | 2 (100%)            | 3 (13.6%)         | 4                   | 1 (25.0%)           | 3 (75.0%)           | 3 (4.4%)            |
| HPV-11    | 0                   | –                   | 0 (0%)            | 1                   | –                   | 1 (100%)           | 4 (5.6%)            |
| HPV-26    | 1                   | 1 (100%)            | 1 (4.4%)          | 3                   | 3 (100%)           | 2 (2.9%)            | 4 (1.4%)            |
| HPV-40    | 2                   | –                   | 2 (100%)          | 3 (13.3%)           | 3 (33.3%)           | 6 (66.7%)           | 0 (0%)              |
| HPV-42    | 1                   | 1 (100%)            | –                 | 4                   | 1 (25.0%)           | 3 (75.0%)           | 3 (4.4%)            |
| HPV-53    | 1                   | 1 (100%)            | –                 | 5                   | 2 (20.0%)           | 8 (80.0%)           | 4 (6.4%)            |
| HPV-54    | 5                   | 3 (60.0%)           | 2 (40.0%)         | 2 (10.5%)           | 3 (13.3%)           | 2 (66.7%)           | 4 (5.7%)            |
| HPV-55    | 2                   | 1 (50.0%)           | 1 (50.0%)         | 6 (1.6%)            | 1 (6.7%)           | 5 (83.3%)           | 2 (3.0%)            |
| HPV-61    | 2                   | 1 (50.0%)           | 1 (50.0%)         | 2 (9.1%)            | 2 (40.0%)           | 3 (60.0%)           | 5 (7.4%)            |
| HPV-62    | 0                   | –                   | 0 (0%)            | 4 (12.0%)           | –                   | 3 (100%)           | 2 (2.9%)            |
| HPV-64    | 0                   | –                   | 0 (0%)            | 1                   | –                   | 1 (100%)           | 2 (2.8%)            |
| HPV-66    | 3                   | 2 (66.7%)           | 1 (33.3%)         | 4                   | 2 (28.6%)           | 4 (71.4%)           | 7 (12.1%)           |
| HPV-67    | 2                   | 2 (100%)            | 1 (4.5%)          | 4                   | 2 (28.6%)           | 4 (71.4%)           | 7 (7.5%)            |
| HPV-70    | 1                   | –                   | 1 (100%)          | 4                   | 2 (100%)           | 6 (85.0%)           | 4 (7.5%)            |
| HPV-71    | 1                   | –                   | 1 (100%)          | 4 (100%)            | –                   | 1 (100%)           | 1 (1.4%)            |
| HPV-81    | 3                   | 1 (33.3%)           | 2 (66.7%)         | 1 (4.8%)            | –                   | 1 (100%)           | 3 (4.2%)            |
| HPV-82    | 1                   | –                   | 1 (100%)          | 0 (0%)              | 3 (133.3%)          | 2 (66.7%)           | 2 (2.9%)            |
| HPV-83    | 1                   | 1 (100%)            | 2 (8.7%)          | 2                   | 1 (50.0%)           | 2 (50.0%)           | 1 (4.6%)            |
| HPV-84    | 4                   | 1 (25.0%)           | 3 (75.0%)         | 0 (0%)              | 3                   | 3 (100%)           | 5 (7.1%)            |
| CPe108    | 1                   | 1 (100%)            | –                 | 8                   | 3 (37.5%)           | 5 (62.5%)           | 3 (4.6%)            |
| All low risk infections† | 33                 | 12 (36.4%)          | 21 (63.6%)        | 24                  | 68                  | 15 (22.1%)          | 53 (77.9%)          |

*Among those infected with that serotype at visit 1 (enrolment).
†Cumulative incidence among those uninfected with that serotype at enrolment.
‡Cumulative incidence of genotype-specific infections among 97 women (24 in control and 73 in vaccine arm).
HPV, human papillomavirus.
Epidemiology

factors such as hormonal contraception, or more frequent condom use, these results should be interpreted with caution as our power to detect a significant association was low, and both variables may be a marker of more frequent sexual intercourse or with higher risk partners. Furthermore, since HPV infection is common, the OR should not be interpreted as a risk ratio; for example, with 68% prevalence in those not using hormonal contraception, an OR of 2 reflects a 19% increase in risk.

Cumulative HPV incidence in sexually active young women is high in developed countries. One US study found a cumulative 36 month incidence of 43% in college students. HPV incidence was also high in our study and infection with new HPV types was acquired in two-thirds of sexually active participants over 1 year. This may be an underestimate of the true incidence since some undetected HPV infections may have been acquired and lost between enrolment and 12 months. A recent study of 380 Ugandan women followed for a median of 18.5 months found an HPV incidence of 30.5/100 person-years with a higher incidence of HR than LR types. Reasons for the high incidence reported in our study are unclear since we have limited data on type and age of sexual partners but our results provide an indication of the high infection pressure for HPV in this setting.

Transmission of HPV appears extremely efficient in the early years of sexual activity in this population, with around two-thirds of girls acquiring HPV infection within the first few years following sexual debut. Although over a quarter of participants experienced persistent HPV infection, a predictor for cervical lesion development, most infections were transitory and 73% of HPV genotype-specific infections were cleared within 12 months. Similar clearance rates have been observed in studies in developed countries. The median duration of infection in young sexually active girls in a US study was 8 months. A Brazilian study found that 12-month clearance was higher for LR HPV than for HR HPV types but this was not seen in our study or in a Colombian study. Our study was not powered to measure the effect of vaccine on HPV incidence or persistence.

A high prevalence of HPV infection in young women does not necessarily translate to a high rate of persistent infection, a prerequisite for development of precancerous and cancerous lesions, since most women should clear their HPV infections. The high infection pressure for HPV in this setting means some persistent infections will develop and are likely to lead to higher rates of cervical cancer than observed in developed countries since there is an absence of adequate screening and treatment programmes. The risk of developing cervical cancer will obviously be increased with HIV infection. Recent data suggest that HPV-16 and -18 are associated with 70% or more of cervical cancers in the world, since there is an absence of adequate screening and treatment programmes. The risk of developing cervical cancer will obviously be increased with HIV infection. Recent data suggest that HPV-16 and -18 are associated with 70% or more of cervical cancers in the world, since there is an absence of adequate screening and treatment programmes. The risk of developing cervical cancer will obviously be increased with HIV infection. Recent data suggest that HPV-16 and -18 are associated with 70% or more of cervical cancers in the world. The high infection pressure for HPV in this setting means some persistent infections will develop and are likely to lead to higher rates of cervical cancer than observed in developed countries since there is an absence of adequate screening and treatment programmes. The risk of developing cervical cancer will obviously be increased with HIV infection. Recent data suggest that HPV-16 and -18 are associated with 70% or more of cervical cancers in the world.

In conclusion, we found an extremely high prevalence and incidence of HPV infection in young HIV negative Tanzanian female subjects. The high rates of HPV infection and poor access to cervical screening services have led to Tanzania having one of the highest rates of cervical cancer in the world and therefore it is positive news that Tanzania is planning a national HPV vaccination programme. Since sexual activity was reported in girls aged 14 years and above in this cohort, and because prevalent HPV infection rises quickly after sexual debut, and vaccination is most efficacious in female subjects before they acquire HPV infection, ideally girls <14-years-old should be targeted for vaccination in this population.

Key messages

- Young Tanzanian women in Mwanza have a very high prevalence and incidence of human papillomavirus (HPV) infection, the primary cause of cervical cancer.
- HPV is rapidly acquired after sexual debut.
- HPV vaccination represents an opportunity for primary prevention and should be provided prior to initiation of sexual intercourse.

Author affiliations

1Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
2Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania
3National Institute for Medical Research, Mwanza, Tanzania
4Bugando Medical Centre, Mwanza, Tanzania
5Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Institut Catalá d’Oncologia, Barcelona, Spain
6CIBER Epidemiología, y Salud Publica, Barcelona, Spain

Acknowledgements We thank the Ministry of Health & Social Welfare for permission to conduct and publish the study, Roche for providing the test kits, the UNIC HPV laboratory in Barcelona and Jose Godliness and Ana Esteban for performing the HPV assays.

Contributors DW-J, RJJ and PM conceived the study. DWJ prepared the protocol and had overall responsibility for supervision and conduct of the study. SK supervised the study activities and BG provided clinical supervision. JB coordinated the study and BK supervised the trial teams and data collection. Data analysis was done by KB. Laboratory analysis was supervised by IC and AA in Mwanza and by SDS in Barcelona. DWJ prepared the first draft of the manuscript. All authors commented on and contributed to the final version of the manuscript.

Funding GlaxoSmithKline Biologicals was the funding source for the HPV-021 trial. Additional funding came from the UK Department for International Development. Partial salary support for DWJ and AA and salary support for JB and BK came from GSK Biologicals.

Competing interests DWJ, PM and SS have received grant support from their institutions from GlaxoSmithKline Biologicals. SS has also received grants from Merck & Co.

364 Watson-Jones D, et al. Sex Transm Infect 2013;89:358–365. doi:10.1136/sextrans-2012-050685
Ethics approval London School of Hygiene & Tropical Medicine, UK and National Institute for Medical Research, Tanzania.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/